Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug683 | CBD Isolate Wiki | 0.71 |
| drug1581 | Full Spectrum CBD Oil Wiki | 0.71 |
| drug4310 | Woebot Substance Use Disorder Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000437 | Alcoholism NIH | 0.53 |
| D015775 | Fractures, Stress NIH | 0.50 |
| D019966 | Substance-Related Disorders NIH | 0.39 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 474121 in healthy male subjects following oral administration of single rising doses.
The main objectives of this trial are to investigate safety and tolerability of BI 474121 in healthy male and female young and elderly subjects following oral administration of multiple rising doses per day over 14 days.
Description: After the first dose of BI 474121
Measure: Area under the concentration-time curve of the analyte in plasma from 0 to 24h (AUC0-24) Time: Up to Day 1Description: After the first dose of BI 474121
Measure: Maximum measured concentration of the analyte in plasma (Cmax) Time: Up to Day 1Description: After the last dose of BI 474121
Measure: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) Time: Up to Day 14Description: After the last dose of BI 474121
Measure: Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss) Time: Up to Day 14Description: After each of three doses Midazolam
Measure: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) Time: Up to Day 14Description: After each of three doses Midazolam
Measure: Maximum measured concentration of the analyte in plasma (Cmax) Time: Up to Day 14Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports